JEUVEAU IS THE NEW BOTOX

02-21-19 | Posted by Wendy Lewis

At long last, the much anticipated Jeuveau (TM) from Evolus received a nod from the US FDA.

Evolus (EOLS) is a relatively new medical aesthetics company with a stellar team of aesthetics industry veterans to their credit, who have brought the first 900 kDA botulinum toxin (DWP-450) – touted to be the same as BOTOX (Allergan) – to market. It hails from Daewong Bio Inc in Seoul, South Korea, which is fast become the de facto capital of all things aesthetic in Asia, and Evolus has exclusive rights to this toxin for the US market.

According to New York City plastic surgeon Z. Paul Lorenc, MD, who was an investigator for the Phase II and Phase III studies for Evolus, “We found that the safety profile, results and duration of Jeuveau is very good. I believe that it will find its place in the US market based on pricing and marketing to a new segment of patients.”

Jeuveau’s entry is kind of a huge deal because we have not had a new FDA approved neuromodulator (doc speak for toxin) for cosmetic indications since Xeomin (Merz) received approval in July 2011 for glabellar lines (the frown lines between the brows). Before that, it was 2009 when Dysport (Galderma) entered the cosmetic market. Of course, outside the US, there are many more variations for doctors and patients with facial lines, creases and other imperfections to choose from.

evolus.com

One might be inclined to dub Jeuveau the “happy” toxin, as evidenced by the cheery branding and bright red butterfly shaped logo of Evolus. To a newbie toxin-user, it may appear decidedly non-threatening, which I suppose is the general idea.

According to New York City facial plastic surgeon Jennifer Levine, “It is always good to have more choices in terms of products available as a physician and hopefully Jeuveau’s entrance into the US market will generate even more awareness of the myriad uses for botulinum toxins among patients.”

Stay tuned for a Spring 2019 U.S. launch at an aesthetic doctor’s office near you. Now this could get interesting as the toxin wars heat up…